Assessment of aneuploidy formation in human blastocysts resulting from cryopreserved donor eggs by Aimin Deng & Wei-Hua Wang
Deng and Wang Molecular Cytogenetics  (2015) 8:12 
DOI 10.1186/s13039-015-0117-8RESEARCH Open AccessAssessment of aneuploidy formation in human
blastocysts resulting from cryopreserved donor
eggs
Aimin Deng1 and Wei-Hua Wang2,3*Abstract
Background: Increased embryo implantation rates were reported after transfer of euploid embryos selected by
preimplantation genetic screening (PGS). Egg cryopreservation by vitrification has become one of the most
important assisted human reproduction technologies. Although reports indicate that development and implantation
of human embryos derived from frozen donor eggs are comparative to fresh eggs, it is still unknown whether egg
vitrification increases chromosomal abnormalities in eggs, which in turn causes formation of embryonic aneuploidy.
Therefore, in this study, we evaluated the aneuploidy formation in the blastocysts derived from frozen donor eggs
and also evaluated the efficiency of egg vitrification as an advanced technology for egg cryopreservation.
Results: In this study, donated human eggs from young women were cryopreserved by vitrification and PGS was
performed in the resulted blastocysts by DNA microarray. A total of 764 frozen eggs from 75 egg thawing cycles
were warmed and 38 blastocysts were biopsied for PGS before embryo transfer. A 97.1% of egg survival rate was
obtained and 59.1% of embryos developed to blastocyst stage. After biopsy and PGS, it was found that 84.2% of
blastocysts were euploid and 15.8% were aneuploid. Aneuploidy rates varied among donors. Transfers of blastocysts
without PGS resulted in higher clinical pregnancy and implantation rates as compared with transfer of blastocysts
with PGS.
Conclusions: Although the overall aneuploidy rate was low in the blastocysts derived from frozen donor eggs, high
aneuploidy rates were observed in the embryos resulting from some donated eggs. Clinical pregnancy rate was not
improved by PGS of embryos resulting from donor eggs, indicating that PGS may not be necessary for embryos
derived from donor eggs in most cases.
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Egg cryopreservation has become one of the key assisted
reproduction technologies (ART) in humans [1-7]. Suc-
cessful egg cryopreservation has allowed for the estab-
lishment of frozen egg banks [8-10]. A few studies have
reported high clinical pregnancy and live birth rates after
transfer of the resulting embryos with vitrified/warmed
human eggs [7-11]. It has also been reported that embryo
development, clinical pregnancy and embryo implantation
rates are similar between fresh and cryopreserved eggs in* Correspondence: wangweihua11@yahoo.com
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unless otherwise stated.some egg donation programs [7,12-14]. There was no ap-
parent increase in congenital anomalies [15] and other
abnormities [4] in the babies derived from frozen eggs.
Based on the accumulated clinical data published in recent
years, the American Society for Reproduction Medicine
has opined that oocyte cryopreservation should no longer
be considered experimental since 2012.
Previously it has been found that freezing can cause
spindle abnormalities [16] and chromosome misalign-
ment [17] in human eggs, which in turn may increase
the occurrence of aneuploid embryos after fertilization
[18-21]. When vitrification, a new egg cryopreservation
technology, was compared with slow egg freezing, it was
found that vitrified eggs had a better survival rate than
slow freezing [22]. The morphology, meiotic spindle,tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of the outcome of donor egg
cryopreservation/warming cycles
Total warming cycles 75
Average age of recipients 41.6 ± 4.83#
Total No. of eggs warmed 647
Average No. of eggs per recipient 8.6 ± 1.4#
Total No. of eggs survived (%)* 627 (97.1)
Total No. of eggs fertilized (%)** 535 (85.3)
Total No. of eggs cleaved (%)*** 477 (89.2)
Total No. of blastocysts (%)**** 282 (59.1)
#Mean ± SD.
*Percentage of warmed eggs.
**Percentage of survived eggs.
***Percentage of fertilized eggs.
****Percentage of cleaved eggs.
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also different between vitrification and slow freezing
[23,24]. These data indicate that vitrification is more effi-
cient to cryopreserve human eggs than slow freezing. Al-
though Coticchio et al. reported that vitrification may
also increase chromosome misalignment in human eggs
[17], it was noticed that ultra-structure alternation in
human eggs after vitrification was related to vitrification
methods, especially cooling rate [25]. Recently, Forman
et al. reported that vitrification did not increase embry-
onic aneuploidy formation in young women undergoing
in vitro fertilization (IVF) [26]. This may indicate that
human eggs can recover normally (structure and function)
after minor changes caused by vitrification and warming if
optimal methods are used.
Aneuploidy is one of the most essential factors affect-
ing embryo implantation and most of the birth defects
are also caused by embryonic aneuploidy [18,19]. It has
been reported that aneuploidy rate in preimplantation
embryos is increased in patients of advanced maternal
age [19,21,27]. Recently, it has also been found that high
proportions of human embryos were aneuploid in younger
patients undergoing IVF [28,29]. Donor eggs are usually
collected from healthy, young and fertile women and
should have normal quality and chromosomal integrity.
However, these eggs are collected after controlled ovarian
stimulation with high dosages of external gondotropins
and then the eggs are exposed to in vitro environments for
manipulations; many aspects, especially the genetic and
epigenetic alternations, are still unknown.
Preimplantation genetic screening (PGS) by all chromo-
some DNA microarray has become available in human
ART, which has provided an approach to examine struc-
tural and numeral abnormalities in all chromosomes in the
preimplantation embryos [27,29-31]. It has been found that
PGS especially benefits the patients of advanced maternal
ages, recurrent miscarriage and previous spontaneous mis-
carriage, as aneuploidy is the main reason for unsuccessful
embryo implantation in these populations of patients
[27,30-33]. However, such information is still missing in
the patients who receive the cryopreseved donor eggs.
If vitrification can cause some meiotic spindle and/or
chromosomal alternations, PGS may be useful for selecting
normal embryos. Therefore, in the present study, we retro-
spectively collected data on PGS of blastocysts derived
from frozen donor eggs and aimed to analyze the aneu-
ploidy in human embryos resulting from cryopreserved
donor eggs and also to evaluate the efficiency of egg vitrifi-
cation as an advanced technology for egg cryopreservation.
Results
Egg survival and embryo development
As shown in Table 1, a total of 647 eggs for 75 recipient
cycles were warmed during this data collection periodand each recipient received average of 8.6 ± 1.4 eggs
(range from 5–11). After warming and insemination,
627 eggs (97.1%) survived and 535 (85.3%) fertilized nor-
mally (2 pronuclei). Out of 477 (89.2% cleavage rate)
cleaved eggs, 282 developed to blastocysts with a blasto-
cyst formation rate of 59.1%.
Aneuploidy in the blastocysts derived from frozen
donor eggs
As shown in Table 2, 8 recipients received 74 eggs from
8 anonymous donors. The donor ages were between 21–
31, and 199 eggs (from 10–51 per donor) were retrieved
and 179 (90.0%) were matured at Metaphase II stage.
Eight recipients aged between 40 and 52 years old re-
ceived 74 eggs that were warmed with a 97.3% survival
rate. After insemination, 64 (88.9%) eggs fertilized nor-
mally, 56 (87.5%) cleaved and 38 (67.9%) developed to
blastocysts. Blastocyst rates were 25-80%. All blastocysts
were biopsied and DNA microarray was performed for
aneuploidy screening. Out of 38 blastocysts, 32 (84.2%)
were euploid, and 6 (15.8%) were aneuploid. No aneu-
ploid embryo was observed in four cases, while 12-50%
of aneuploid embryos were observed in other 4 cases.
Some PGS charts were shown in Figure 1 in which eu-
ploid and aneuploid samples were presented.
When we investigated whether stimulation had a cor-
relation with aneuploid embryos from donor eggs, as
shown in Table 2, we found that aneuploid embryos
were present in 3 out of 4 donors who had leuprolide
acetate trigger due to high level of E2 while aneuploid
embryos were present only in 1 out of 4 donors who had
regular hCG (Ovidrel) trigger. This is not related with
the total dosage of gonadotropins used, but it may de-
pend on the individual response (such as high estradiol
level) to external gonadotropins. Detailed chromo-
some information of all abnormal embryos was listed
in Table 3. Abnormal embryos were not reanalyzed due to
cost reasons.
Table 2 DNA microarray analysis of all chromosomes in the blastocysts produced from vitrified donor eggs
Case # 1 2 3 4 5 6 7 8 Total (%)
Donor age 29 22 21 24 23 29 22 31 25.1 ± 3.9*
Total gonadotropins 3450 3000 1725 1725 1725 1725 4275 2250
E2 at trigging day 3426 4244 5228 3928 8398 4238 2485 9046
Trigger Ovi Ovi Lup Lup Lup Ovi Ovi Lup
No. of eggs retrieved 22 51 18 10 28 28 21 21 199
No. of eggs matured 20 45 14 10 27 28 15 20 179 (90.0)
Age of recipient 51 41 43 40 43 48 44 52 45.3 ± 4.5*
No. of eggs warmed 10 10 10 10 8 8 8 10 74
No. of eggs survived 10 8 10 10 8 8 8 10 72 (97.3)
No. of eggs fertilized 8 7 9 10 7 7 6 10 64 (88.9)
No. of eggs cleaved 8 5 4 10 7 6 6 10 56 (87.5)
No. of blastocysts 6 4 1 8 4 3 4 8 38
% of blastocyst 75 80 25 80 57 50 67 80 (67.9)
No. of euploid blasts 6 3 1 6 2 3 4 7 32
% of euploid blasts 100 75 100 75 50 100 100 88 (84.2)
No. of aneuploid blasts 0 1 0 2 2 0 0 1 6
% of aneuploid blasts 0 25 0 25 50 0 0 12 (15.8)
Ovi: Ovidrel; Lup: leuprolide acetate.
*Mean ± SD.
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donor eggs
In the present study, 63 cycles had embryo transfers
without PGS, 43 (68.3% per transfer) became biochem-
ically pregnant which was examined about two weeks
after transfer; 40 (63.5% per transfer) became clinically
pregnant and 36 (57.1% per transfer) delivered normal
healthy babies. These data were based on the first fresh
embryo transfer in these patients. Seven patients had
embryo transfer after PGS with either fresh and/or fro-
zen embryos, 4 (57.1% per transfer) transfers resulted in
biochemical pregnancy and 3 became clinically pregnant
(42.9% per transfer) and delivered normal healthy babies
(42.9%). Four patients without PGS and one patient with
PGS did not have embryo transfer so far, so there is no
clinical data available.
Discussion
One of the benefits of egg cryopreservation is the estab-
lishment of frozen donor egg banks in which recipients
and egg donors do not need to synchronize the same
cycle, and recipients can select their donors and/or eggs
whenever they need. Another benefit is that many eggs
are usually retrieved from young egg donors and it is
not necessary to use all eggs to make embryos for one
recipient, and supernumerary eggs can be frozen for
other recipients to use. This makes egg sharing donation
particularly easy among recipients [34,35].Similar to previous studies [1-7], the present study in-
dicates that high survival rates can be obtained after eggs
were cryopreserved with vitrification. Also, high blasto-
cyst development and embryo implantation rates were
obtained with the vitrified/warmed donor eggs. In the
present study, we also provide the first evidence that
high proportions of blastocysts derived from frozen
donor eggs were euploid after PGS. This may indicate
that meiotic spindles recovered normally during vitri-
fication and chromosomes segregate correctly after
vitrification/warming. As of our knowledge, this is the first
study to be performed to screen aneuploidy in the embryos
derived from vitrified donor eggs.
Egg vitrification, as a new cryopreservation technology,
has been used in human IVF for a few years and there
are still many concerns, such as viability (not just sur-
vival rate), genetic stability and epigenetic status [24].
The present study indicates that meiotic spindles and/or
chromosomes may be quite stable in the young donor
eggs after vitrification and warming as shown by low
aneuploidy rate in the derived blastocysts. Although
such a conclusion is based on a limited number of
embryos (38 blastocysts), it provides information that
aneuploidy rate is very low in young fertile women (egg
donors) and vitrification may not increase its rate. This
conclusion is also supported by high implantation rates
of embryos derived from donors [3,7,10-14], and from
young fertile [35] and infertile women [26].
Figure 1 Microarray charts of blastocysts derived from
vitrified donor eggs. A) arr(1–22,X) × 2 B) arr(1–22) × 2,(XY) × 1
C) arr(18) × 1; D) arr(2) × 3,(5) × 3,(6) × 3,(11) × 3. Red arrows indicate
abnormal chromosomes.
Table 3 Detailed chromosome information of the
abnormal embryos derived from donor eggs
Sample number Chromosome information*
1 arr(18) × 3
2 arr(8) × 1
3 arr(2) × 3, (5) × 3, (6) × 3, (11) × 3
4 arr(13) × 3
5 arr(3) × 1, (4) × 1, (14) × 1, (10) × 3, (11) × 3
6 arr(X) × 1
*Microarray chromosome information was named by referring to Cytogenetic
Nomenclatures ISCN 2013 [44].
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tors affecting human IVF success and such an affect
could be reduced by transfer of euploid embryos [27,29].
An age-related reduced embryo implantation can also beovercome by the transfer of selected embryos with PGS
[27]. Aneuploid embryos are present in infertile patients
of various maternal ages with an increased tendency as
maternal ages are increased [27,29,31,36]. Embryos from
healthy egg donors should have low embryonic aneu-
ploidy rates, but direct information is still missing due
to the fact that high pregnancy rates can be obtained
with donor eggs and PGS for embryos derived from
donor eggs are not routinely performed due to cost and
necessity.
By contrast, for egg cryopreservation, due to meiotic
spindle’s sensitivity to temperature [37-39], it is possible
that spindle damage occurs during egg in vitro manipu-
lation [37-39] and cryopreservation [16,17]. Although
vitrification can provide a better egg survival than slow
freezing, the meiotic spindle and/or chromosomal distri-
bution must have undergone dynamic changes due to
temperature fluctuations during vitrification and warming.
It is possible that suboptimal protocols may negatively in-
fluence the normal meiosis after egg cryopreservation
[25]. It is necessary to functionally study meiotic spindle
recovery and chromosome distribution in frozen eggs.
However, due to the shortage of donor eggs for the related
studies, such information is still unavailable. The alterna-
tive way to investigate the chromosomal changes after egg
cryopreservation may be the examination of embryonic
aneuploidy formation, which can indirectly provide infor-
mation of whether the vitrification affects the meiotic
spindle recovery, chromosome alignment, normal meiosis
and subsequent mitosis without destroying eggs. Our
present study with DNA microarray of blastocysts derived
from frozen donor eggs indicates that aneuploidy rate is
low in donor eggs and vitrification/warming may not in-
crease the rate.
Other indirect evidence that vitrification/warming may
not increase embryonic aneuploidy rates is the direct
comparison of embryo implantation between fresh and
frozen eggs from the same donors. Such studies have
been performed in a few egg donor programs and no
differences were observed in terms of blastocyst forma-
tion, pregnancy and implantation rates [3,7,10-13].
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formation in human embryos derived from fresh and
frozen eggs that were collected from the same young
patients and found that vitrification did not increase an-
euploidy formation either in arrested embryos or blasto-
cysts [26]. This is the first direct study with DNA
microarray to indicate that vitrification is a safe and ef-
fective procedure to preserve human eggs. In Forman’s
study, the authors found that aneuploidy rate of human
eggs after vitrification was about 20% [26], which is
lower than that (40%) reported by Yang et al. [29]. Both
studies examined the embryos from IVF patients. In the
present study, we found that the aneuploid rate was
15.8% from the egg donors who are healthy young
women. In the present studies, all embryos from 4 do-
nors were normal euploid while 25-50% of embryos
from the other four donors were aneuploid. The reasons
for the aneuploidy in these eggs are still unknown but it
may be related to donors or donor stimulation as there
were variations among donors.
In a previous study, it was reported that extra ovarian
stimulation can increase aneuploid formation in human
IVF [40]. In the present study, we also found such a ten-
dency that high estradiol level may be related to aneu-
ploidy formation. However, a comprehensive conclusion
may need more clinical data. These data may indicate
that aneuploidy is a donor specific, not a procedure
(vitrification) specific and that egg vitrification may
not increase chromosomal abnormalities and current
vitrification protocols for eggs are efficiency.
Blastocyst transfer has been widely adapted in many
IVF clinics and it has also been suggested that blastocyst
transfer is an option for egg thawing cycles [41]. Many
IVF clinics still use Day 3 embryo transfer for egg thaw-
ing cycles, and this may be due to the worries of low
blastocyst development with frozen eggs. However, based
on a few direct comparison studies, it would appear that
the same blastocyst development rates could be obtained
with fresh and frozen human donor eggs [7,12-14].
In the present study, we did not find any benefit of
PGS on the embryo implantation and/or baby delivery
rates, while a lower birth rate was found if PGS was ap-
plied to the embryos from frozen eggs. There are a few
possibilities to explain this situation. First of all, embryo
biopsy may affect the embryo viability although such a
procedure does not affect the viability of blastocysts de-
rived from fresh eggs [27,29,31]. We found that slow
embryo development was present in the vitrified eggs in
some cases and the blastocysts did not expand com-
pletely at day 5, thus trophectoderm cell biopsy may
affect the developmental potential of embryos in the
early blastocysts. The second reason may be due to
the delayed embryo transfer after biopsy and PGS. In
the present study, we performed biopsy at day 5 andtransferred the embryos at day 6 after the PGS results
became available in some cases. The blastocyst viability
may be affected by the procedures. However, this situ-
ation was not observed in Forman’s study [26], in which
PGS was performed on site and the time for PGS on site
can be reduced or biopsy may be performed only on ex-
panded blastocysts, which is the optimal embryo stage
to perform a biopsy.
Conclusions
In conclusion, our study indicates that high egg survival
rates and blastocyst development rates can be obtained
with vitrified human donor eggs. Acceptable pregnancy
and implantation can also be obtained with transfer of
the blastocysts resulting from frozen donor eggs. Be-
cause donor eggs are from healthy and young women,
the embryonic aneuploidy rate is low in this population
of embryos and vitrification may not increase chromo-
somal abnormalities, aneuploidy screening may be not
necessary in most cases. However, if the donors are over
stimulated by external gonadotropins and have ex-
tremely high E2 levels, there may be an increased possi-
bility to have some aneuploid embryos, and PGS may be




Patients undergoing IVF, egg donation and PGS signed
written consents for all kinds of laboratory and clinical
procedures. All egg donors were anonymous in the
present study. The data was retrospectively collected
from the medical records and the study was approved by
Institutional Review Board (NEIRB 14–504).
Donor stimulation and egg retrieval
Egg donors were stimulated with a combination of
Follistim (Organo Inc, Roseland NJ, USA), Gonal-F
(EMD Serono, Rockland MA, USA), Menopur (Ferring
Pharmaceuticals, Parsippany NJ, USA) and/or Bravella
(Ferring Pharmaceuticals) beginning 2–3 days after the
onset of menses. The initial starting total dose was 150–
375 IU and was adjusted subsequently as the stimulation
progressed. To prevent an luteal hormone surge, a
GnRH antagonist, Ganirelix or Cetrorelix (Organo Inc.),
was given when the leading follicle was 13–14 mm or
when the estradiol level was 400 pg/ml. Human chori-
onic gonadotropin (hCG), Ovidrel (Serono USA), or a
GnRH agonist, leuprolide acetate (Teva North America,
North Wales PA, USA), was injected to induce final oo-
cyte maturation when at least two dominant follicles
reached a diameter of >18 mm. Eggs were retrieved under
IV sedation via transvaginal ultrasound between 35–37
hours after hCG or leuprolide acetate administration.
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an egg bank if they were not used freshly for insemination
for the recipients who were prepared for embryo transfer.
In some cases of donation, all eggs were cryopreserved and
placed into the egg bank.
Egg vitrification
Oocytes were cultured for 3–5 hours before removing
the surrounding cumulus cells in a HEPES-buffered glo-
bal medium (IVFonline, CT, USA) containing 40 iu hyal-
uronidase. Only mature (metaphase II) oocytes were
vitrified with Irvine vitrification kits (Irvine Scientific,
Irvine CA USA). All procedures were performed at room
temperature (22-25°C) based on the procedures reported
previously [7].
Egg warming and insemination
Egg warming was based on the procedures previously re-
ported [7]. Briefly, straws were removed from liquid ni-
trogen and the tips of the straws with eggs were quickly
placed in 1 ml 1.0 M sucrose solution that had been
warmed at 37°C in an organ culture dish. After 1 minute
in the sucrose solution, eggs were transferred to 1 ml 0.5
M sucrose solution for 3 minutes and then to 1 ml basic
solution for 2 × 5 minutes. These procedures were per-
formed at room temperature (22-25°C). After warming,
eggs were washed with Global medium supplemented
with 10% serum protein substitute (SPS) (IVFonline) and
then cultured in the same medium. Egg survival status
was evaluated based on morphology after completion of
the warming procedures. All survived eggs were insemi-
nated by intracytoplasmic sperm injection (ICSI) 2–3
hours after warming.
Embryo culture and embryo biopsy
All eggs were cultured in Global medium supplemented
with 10% SPS after ICSI. Fertilization was examined 16–
18 hours after ICSI and normally fertilized eggs (zygotes)
were cultured in Global medium supplemented with
10% SPS at 37°C in a humidified atmosphere of 5.5%
CO2, 5% O2 and balanced nitrogen until day 6 after in-
seminations. On day 5, embryo development was evalu-
ated and the best 1–2 embryos depending on embryo
quality were transferred. If the recipients were not ready
for transfer or PGS was requested, day 6 embryo trans-
fer (PGS cases) or frozen embryo transfer (FET) were
performed.
For PGS embryos, at day 3, a hole about 20 μm in
diameter was opened in the zona pellucida using the
ZILOS-tk™ laser system (Hamilton Thorn Bioscience
Inc., MA USA). On day 5, embryos were examined with
an inverted microscope, and if trophectoderm (TE) cells
started to hatch from the opening in the zona pellucida,
some hatched TE cells (~10) were biopsied using a20 μm polished biopsy pipette with assisted cutting
by laser. Blastocyst biopsy was performed on TE cells
at days 5 or 6 depending on blastocyst development.
After biopsy, the embryo proper was cultured in Global
medium supplemented with 10% SPS for 1–2 hrs before
vitrification or continued in the culture until day 6 if a
fresh embryo transfer was required. The biopsied cells
were washed with a washing buffer provided by PGS la-
boratory (PacGenomics Inc, CA, USA), placed in tubes
with cell lysis buffer and were then frozen at −20°C before
being processed for microarray.
Blastocyst vitrification, warming and embryo transfer
Blastocysts were vitrified after the blastocoele was com-
pletely collapsed according to a previous method [42] by
using Irvine vitrification kit. Briefly, blastocysts were
equilibrated in the equilibration solution for 2 minutes
on a warming stage (37°C). The blastocysts were then
transferred into the vitrification solution and then
loaded onto a vitrification straw within 45 seconds. All
embryos were vitrified individually and then stored in li-
quid nitrogen until warming for FET.
For warming, blastocysts were exposed to 1 M warmed
(37°C) sucrose solution for 1 minute. Blastocysts were
then transferred to 0.5 M sucrose solution for 3 minutes
and to a basic solution for 10 minutes with a solution
change after 5 minutes at room temperature. After com-
pletion of the warming process, blastocysts were washed
with Global medium supplemented with 10% SPS
and then cultured in the same medium for 2–4 hrs
before transfer. Blastocyst quality was assessed using
standard assessments developed by the Society of Assisted
Reproductive Technology [43].
Microarray of biopsied samples with oligo NimbleGen
platform
Microarray of biopsied samples was performed based on
a previous reported procedure [31]. Briefly, samples were
lysed and the cells’ genomic DNA was amplified using
Rubicon whole-genome amplification kit (Rubicon, MI,
USA). The DNA concentration of purified samples was
measured using Nanodrop 2000 (Thermo, DE, USA)
and the samples were then labeled with Cy3 using the
NG dual color labeling kit according to manufacturer’s
instructions (Roche NimbleGen, IN, USA). Labeled sam-
ples were mixed with Cy5 control labeled samples, dried,
dissolved and loaded on NimbleGen 6 × 630 K compara-
tive genome hybridization (CGH) tiling array following
the NimbleGen hybridization protocol. Reference DNA
(both male and female were used) for array was obtained
from Promega (Promega Corporation, Madison, WI
USA). After overnight hybridization, arrays were washed
following the NimbleGen washing protocol. Arrays were
dried and scanned with a NimbleGen MS200 scanner
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lution. Scanned images were analyzed by Deva 1.1 soft-
ware (Roche NimbleGen, IN, USA) and the normalized
ratio of each sample versus the control was retrieved fol-
lowing the NimbleGen CGH data analysis protocol. Fi-
nally, the normalized ratio of each sample was input into
Nexus 6.1 software (Biodiscovery, CA, USA) and the
Log2 ratio result of each sample’s whole genome view is
presented. Human Genome Build 19 (hg19) was used in
the present study. Microarray chromosome information
was named by referring to Cytogenetic Nomenclatures
ISCN 2013 [44].
Patient preparation for embryo transfer
All patients for embryo transfer received estradiol orally
and transvaginally. Intramuscular administration of pro-
gesterone oil was initiated after about 14 days of estradiol
treatment. Endometrium thickness was measured on the
day of progesterone administration. Embryo transfer oc-
curred on the sixth or seventh day of progesterone ad-
ministration and progesterone was continued until the
first serum β-hCG test two weeks after transfer. Ongoing
pregnancies were supported by continued estradiol and
progesterone.
Pregnancy and live birth rate assessment
Fourteen days after embryo transfer, pregnancy was
checked by a serum β-hCG assay. When the β-hCG
was > 5 mIU/mL the patients were regarded as hav-
ing a biochemical pregnancy. Four weeks after em-
bryo transfer, when a gestational sac and a heart beat
appeared ultrasonographically, the patients were diag-
nosed as having a clinical pregnancy. The live birth
rates indicated as live birth per embryo transfers.
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